For decades, the idea of teaching the immune system to recognize and destroy a patient's own tumor has been more promise than reality — but the therapeutic landscape is shifting. The convergence of mRNA technology, neoantigen mapping, and AI-driven antigen selection is producing a new generation of personalized cancer vaccines that, unlike earlier efforts, show clinically meaningful reductions in recurrence risk and improved survival signals.
This comprehensive review in Signal Transduction and Targeted Therapy surveys the full architecture of personalized cancer vaccine platforms — DNA-, mRNA-, peptide-, dendritic cell-, and whole-cell-based approaches — and maps the core immunological barriers each must overcome. Sipuleucel-T remains the sole FDA-approved therapeutic cancer vaccine after nearly two decades, underscoring how difficult clinical translation has been. Against that backdrop, recent Phase II and III data from Moderna's mRNA-4157 (mRNA-1283 backbone combined with individualized neoantigens) and BioNTech's autogene cevumeran represent a quantifiable step forward, with recurrence risk reductions documented across melanoma and pancreatic ductal adenocarcinoma — two historically treatment-resistant malignancies. The review also highlights nanovaccine delivery systems — lipid-polymer hybrids, biomimetic membranes, and stimulus-responsive nanomaterials — that enable simultaneous delivery of neoantigens alongside immunostimulatory agonists, improving lymph node targeting and dendritic cell cross-presentation efficiency.
Placing this in context, the review arrives as immune-oncology enters what may be its most technically sophisticated phase. The integration of whole-exome sequencing, AI-based neoantigen prioritization, and lipid nanoparticle delivery — tools largely codified during COVID-19 vaccine development — has materially shortened the manufacturing timeline for individualized constructs. The key limitation the review honestly confronts is tumor heterogeneity and immunosuppressive microenvironments, which can blunt even well-designed vaccines. Most supporting trial data are still early-phase, and long-term survival endpoints remain unconfirmed. Nevertheless, the convergence of multiple validated technologies in a single therapeutic modality makes this arguably one of the more paradigm-shifting developments in oncology over the next decade.